Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
Study Details
Study Description
Brief Summary
This is a two-way (retrospective and prospective) study of COVID-19 infection in an observational cohort of patients with chronic hepatitis B treated with antiviral therapy. Patients with chronic hepatitis B who received anti-HBV treatment in the Second Department of Hepatology, Beijing Ditan Hospital Affiliated to Capital Medical University from February 2022 to December 2023 were enrolled. After enrollment, demographic data of patients, information on antiviral treatment of chronic hepatitis B, COVID-19 vaccination, COVID-19 infection and COVID-19 incidence and treatment from January 2022 to pre enrollment, and data on HBV virus and serology, clinical biochemistry, liver and lung imaging, COVID-19 nucleic acid and COVID-19 antibody examination of patients were collected. After enrollment, prospective anti-HBV treatment, HBV virology, clinical biochemistry, liver imaging and COVID-19 infection and morbidity were observed. The patients with COVID-19 infection during the prospective observation period were observed for COVID-19 infection, onset and treatment, including body temperature, clinical symptoms, signs, cardiac examination, pulmonary imaging, COVID-19, clinical biochemistry, disease severity, time of virus negative conversion, hospital stay and outcome. The influence of COVID-19 infection on liver disease and the influence of interferon anti-HBV treatment on COVID-19 infection, its pathogenesis and prognosis were studied.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This is a two-way (retrospective+prospective) study of COVID-19 infection in an observational cohort of patients with chronic hepatitis B treated with antiviral therapy. Patients with chronic hepatitis B who received anti-HBV treatment in the Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University from February 2022 to December 2023 were enrolled. After enrollment, demographic data of patients, information on antiviral treatment of chronic hepatitis B, COVID-19 vaccination, COVID-19 infection and COVID-19 incidence and treatment from January 2022 to pre enrollment, and data on hepatitis B virus and serology, clinical biochemistry, liver and lung imaging, COVID-19 nucleic acid and COVID-19 antibody examination of patients were collected. After enrollment, prospective anti hepatitis B virus treatment, HBV virology, clinical biochemistry, liver imaging and COVID-19 infection and morbidity were observed. The patients with COVID-19 infection during the prospective observation period were observed for COVID-19 infection, onset and treatment, including body temperature, clinical symptoms, signs, cardiac examination, pulmonary imaging, COVID-19, clinical biochemistry, disease severity, time of virus negative conversion, hospital stay and outcome. The influence of COVID-19 infection on liver disease and the influence of interferon anti hepatitis B virus treatment on COVID-19 infection, its pathogenesis and prognosis were explored.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Interferon treatment group Patients with chronic hepatitis B who received antiviral treatment with Interferon at the Second Department of Hepatology, Beijing Ditan Hospital Affiliated to Capital Medical University from February 2022 to December 2023 were enrolled. |
Drug: Interferon
The naive treated patients with chronic hepatitis B were given antiviral treatment with interferon according to their condition.
Other Names:
|
| nucleoside analogues treatment group Patients with chronic hepatitis B who received antiviral treatment with nucleoside analogues at the Second Department of Hepatology, Beijing Ditan Hospital Affiliated to Capital Medical University from February 2022 to December 2023 were enrolled |
Drug: nucleoside analogues
The naive treated patients with chronic hepatitis B were given antiviral treatment with nucleoside analogues according to their condition.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- The rate of COVID-19 infection. [48 weeks after therapy]
The rate of chronic hepatitis B patients infected with COVID-19 after initial antiviral treatment.
Secondary Outcome Measures
- The rate of severe disease after COVID-19 infection. [48 weeks after therapy]
The rate of severe disease after COVID-19 infection for chronic hepatitis B patients after initial antiviral treatment.
- The hospitalization rate and duration of COVID-19. [48 weeks after therapy]
The hospitalization rate and duration of COVID-19 for chronic hepatitis B patients after initial antiviral treatment.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
- HBsAg positive for 6 months.
-
- Patients undergoing initial or ongoing antiviral treatment.
-
- HBeAg status and HBV DNA level are not limited.
Exclusion Criteria:
-
- Patients with decompensated liver cirrhosis or previous decompensated liver cirrhosis.
-
- At the same time, it is associated with other viral infections, such as hepatitis A virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, HIV, etc. - 3) Accompanied with other serious physical and mental diseases, including uncontrolled primary kidney, heart, lung, vascular, nervous, digestive, severe metabolic diseases (such as uncontrolled hyperthyroidism, diabetes, serious complications, adrenal diseases, etc.), immunodeficiency disease, and accompanied with serious infection; History of active or suspected malignant tumors or malignant tumors.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Hepatology Division 2, Beijing Ditan Hospital | Beijing | Beijing | China | 100015 |
Sponsors and Collaborators
- Beijing Ditan Hospital
Investigators
- Principal Investigator: Yao Xie, Doctor, Beijing Ditan Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DTXY26